Media Coverage Continues to Highlight New Research by Dr. Kamel Khalili and Colleagues at the Lewis Katz School of Medicine and University of Nebraska Medical Center on Dual Gene-Editing Approach to Eliminate HIV Infection

Gene-editing therapy aimed at two targets – HIV-1, the virus that causes AIDS, and CCR5, the co-receptor that helps the virus get into cells – can effectively eliminate HIV infection, new research from the Lewis Katz School of Medicine at Temple University and the University of Nebraska Medical Center shows. The study, published online in the journal the Proceedings of the National Academy of Sciences, is the first to combine a dual gene-editing strategy with the antiretroviral drugs to cure animals of HIV-1. A POZ article on the news included comments from Kamel Khalili, PhD, Laura H. Carnell Professor and Chair of the Department of Microbiology, Immunology, and Inflammation; Director of the Center for Neurovirology and Gene Editing; and Director of the Comprehensive NeuroAIDS Center at the Katz School of Medicine, about the findings. Dr. Khalili is also one of the senior investigators on the new study.